241 related articles for article (PubMed ID: 33761144)
1. Hematopoietic expression of a chimeric murine-human CALR oncoprotein allows the assessment of anti-CALR antibody immunotherapies in vivo.
Achyutuni S; Nivarthi H; Majoros A; Hug E; Schueller C; Jia R; Varga C; Schuster M; Senekowitsch M; Tsiantoulas D; Kavirayani A; Binder CJ; Bock C; Zagrijtschuk O; Kralovics R
Am J Hematol; 2021 Jun; 96(6):698-707. PubMed ID: 33761144
[TBL] [Abstract][Full Text] [Related]
2. Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN.
Benlabiod C; Cacemiro MDC; Nédélec A; Edmond V; Muller D; Rameau P; Touchard L; Gonin P; Constantinescu SN; Raslova H; Villeval JL; Vainchenker W; Plo I; Marty C
Nat Commun; 2020 Sep; 11(1):4886. PubMed ID: 32985500
[TBL] [Abstract][Full Text] [Related]
3. Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice.
Shide K; Kameda T; Kamiunten A; Ozono Y; Tahira Y; Yokomizo-Nakano T; Kubota S; Ono M; Ikeda K; Sekine M; Akizuki K; Nakamura K; Hidaka T; Kubuki Y; Iwakiri H; Hasuike S; Nagata K; Sashida G; Shimoda K
Blood; 2020 Jul; 136(1):106-118. PubMed ID: 32219445
[TBL] [Abstract][Full Text] [Related]
4. Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development.
Balligand T; Achouri Y; Pecquet C; Gaudray G; Colau D; Hug E; Rahmani Y; Stroobant V; Plo I; Vainchenker W; Kralovics R; Van den Eynde BJ; Defour JP; Constantinescu SN
Leukemia; 2020 Feb; 34(2):510-521. PubMed ID: 31471561
[TBL] [Abstract][Full Text] [Related]
5. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
[TBL] [Abstract][Full Text] [Related]
6. Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage.
Li J; Prins D; Park HJ; Grinfeld J; Gonzalez-Arias C; Loughran S; Dovey OM; Klampfl T; Bennett C; Hamilton TL; Pask DC; Sneade R; Williams M; Aungier J; Ghevaert C; Vassiliou GS; Kent DG; Green AR
Blood; 2018 Feb; 131(6):649-661. PubMed ID: 29282219
[TBL] [Abstract][Full Text] [Related]
7. Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish.
Lim KH; Chang YC; Chiang YH; Lin HC; Chang CY; Lin CS; Huang L; Wang WT; Gon-Shen Chen C; Chou WC; Kuo YY
Blood Cancer J; 2016 Oct; 6(10):e481. PubMed ID: 27716741
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
9. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
[TBL] [Abstract][Full Text] [Related]
10. The role of calreticulin mutations in myeloproliferative neoplasms.
Araki M; Komatsu N
Int J Hematol; 2020 Feb; 111(2):200-205. PubMed ID: 31848992
[TBL] [Abstract][Full Text] [Related]
11. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
12. Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations.
Takei H; Edahiro Y; Mano S; Masubuchi N; Mizukami Y; Imai M; Morishita S; Misawa K; Ochiai T; Tsuneda S; Endo H; Nakamura S; Eto K; Ohsaka A; Araki M; Komatsu N
Br J Haematol; 2018 Jun; 181(6):791-802. PubMed ID: 29741776
[TBL] [Abstract][Full Text] [Related]
13. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.
Chen CC; Gau JP; Chou HJ; You JY; Huang CE; Chen YY; Lung J; Chou YS; Leu YW; Lu CH; Lee KD; Tsai YH
Ann Hematol; 2014 Dec; 93(12):2029-36. PubMed ID: 25015052
[TBL] [Abstract][Full Text] [Related]
14. Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.
Shide K; Kameda T; Yamaji T; Sekine M; Inada N; Kamiunten A; Akizuki K; Nakamura K; Hidaka T; Kubuki Y; Shimoda H; Kitanaka A; Honda A; Sawaguchi A; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Hasuike S; Yamamoto S; Nagata K; Shimoda K
Leukemia; 2017 May; 31(5):1136-1144. PubMed ID: 27807369
[TBL] [Abstract][Full Text] [Related]
15. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
Marty C; Pecquet C; Nivarthi H; El-Khoury M; Chachoua I; Tulliez M; Villeval JL; Raslova H; Kralovics R; Constantinescu SN; Plo I; Vainchenker W
Blood; 2016 Mar; 127(10):1317-24. PubMed ID: 26608331
[TBL] [Abstract][Full Text] [Related]
16. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
17. A Novel Pathogenic CALR Exon 9 Mutation in a Patient with Essential Thrombocythemia.
Lee JS; Kim HY; Kim M; Lee YK
Lab Med; 2020 May; 51(3):306-309. PubMed ID: 31626697
[TBL] [Abstract][Full Text] [Related]
18. Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation.
Haunstrup LM; Ebbesen LH; Hansen M; Severinsen MT; Aggerholm A
Exp Hematol; 2018 Dec; 68():62-65. PubMed ID: 30292681
[TBL] [Abstract][Full Text] [Related]
19. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.
Toppaldoddi KR; da Costa Cacemiro M; Bluteau O; Panneau-Schmaltz B; Pioch A; Muller D; Villeval JL; Raslova H; Constantinescu SN; Plo I; Vainchenker W; Marty C
Oncogene; 2019 Mar; 38(10):1651-1660. PubMed ID: 30846848
[TBL] [Abstract][Full Text] [Related]
20. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]